Literature DB >> 15525739

Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma.

Daniel B Brown1, Christopher E Fundakowski, Mauricio Lisker-Melman, Jeffrey S Crippin, Thomas K Pilgram, William Chapman, Michael D Darcy.   

Abstract

PURPOSE: To compare the value of the Child-Pugh and Model for End-stage Liver Disease (MELD) scores to predict patient survival rates after transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC).
MATERIALS AND METHODS: Eighty-seven patients underwent 169 TACE sessions. Child-Pugh and MELD values were calculated before initial treatment. Survival length was tracked from the date of the first TACE procedure. Transplant recipients were censored from the study at the time of surgery. Child-Pugh and MELD scores as well as bilirubin and albumin levels and International Normalized Ratio were placed in high and low categories defined by their respective medians. Patient survival was compared at 3 months, 6 months, 12 months, and 24 months, and patterns were tested with chi2 or Fisher exact tests. Survival over the entire period was examined with Kaplan-Meier analysis and differences were tested with log-rank tests.
RESULTS: Mean and median survival times for all patients were 24 and 17 months, respectively. Sixteen patients were censored for transplantation at a mean of 12.9 months. MELD and Child-Pugh scores correlated well with each other (r = 0.68). Child-Pugh score (r = -0.35, P = .04) correlated more strongly with 12-month survival than did MELD score (r = -0.26, P = .12). After high/low score category division, a significantly greater survival difference was predicted by Child-Pugh score (27.2 months vs 10.3 months; P = .03) versus MELD score (27.5 months vs 15.8 months; P = .19). An albumin level greater than 3.4 g/dL was also associated with significantly improved survival (29.3 months vs 10.1 months; P = .0032). Survival differences between high-risk and low-risk groups at the 3-, 6-, 12-, and 24-month intervals were significant for low Child-Pugh scores and for albumin levels greater than 3.4 g/dL. Statistical significance was not approached at any of the time lengths with MELD scores.
CONCLUSIONS: Child-Pugh score correlates better than MELD score to overall patient survival and is a better predictor than MELD score of survival at specific time points. Of the components of the Child-Pugh and MELD systems, albumin level is the most useful predictor of survival.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15525739     DOI: 10.1097/01.RVI.0000128123.04554.C1

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  14 in total

1.  Nontarget embolization complicating transarterial chemoembolization in a patient with hepatocellular carcinoma.

Authors:  Christopher R Ingraham; Guy E Johnson; Ajit V Nair; Siddharth A Padia
Journal:  Semin Intervent Radiol       Date:  2011-06       Impact factor: 1.513

2.  Imaging predictors of the response to transarterial chemoembolization in patients with hepatocellular carcinoma: a radiological-pathological correlation.

Authors:  Sharon W Kwan; Nicholas Fidelman; Elizabeth Ma; Robert K Kerlan; Francis Y Yao
Journal:  Liver Transpl       Date:  2012-06       Impact factor: 5.799

3.  Comparative study of staging systems for hepatocellular carcinoma in 428 patients treated with radioembolization.

Authors:  Khairuddin Memon; Laura M Kulik; Robert J Lewandowski; Edward Wang; Jonathan Wang; Robert K Ryu; Ryan Hickey; Michael Vouche; Talia Baker; Daniel Ganger; Vanessa L Gates; Ali Habib; Mary F Mulcahy; Riad Salem
Journal:  J Vasc Interv Radiol       Date:  2014-03-07       Impact factor: 3.464

4.  Development and Performance of an Algorithm to Estimate the Child-Turcotte-Pugh Score From a National Electronic Healthcare Database.

Authors:  David E Kaplan; Feng Dai; Ayse Aytaman; Michelle Baytarian; Rena Fox; Kristel Hunt; Astrid Knott; Marcos Pedrosa; Christine Pocha; Rajni Mehta; Mona Duggal; Melissa Skanderson; Adriana Valderrama; Tamar H Taddei
Journal:  Clin Gastroenterol Hepatol       Date:  2015-07-15       Impact factor: 11.382

5.  Evaluation of prognostic factors on recurrence after curative resections for hepatocellular carcinoma.

Authors:  Jae Hyun Han; Dong Goo Kim; Gun Hyung Na; Eun Young Kim; Soo Ho Lee; Tae Ho Hong; Young Kyoung You
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

Review 6.  Liver embolizations in oncology: a review. Part I. Arterial (chemo)embolizations.

Authors:  Peter Gunvén
Journal:  Med Oncol       Date:  2007-08-03       Impact factor: 3.064

7.  A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer.

Authors:  L Kadalayil; R Benini; L Pallan; J O'Beirne; L Marelli; D Yu; A Hackshaw; R Fox; P Johnson; A K Burroughs; D H Palmer; T Meyer
Journal:  Ann Oncol       Date:  2013-07-14       Impact factor: 32.976

8.  Recalibrating the Child-Turcotte-Pugh Score to Improve Prediction of Transplant-Free Survival in Patients with Cirrhosis.

Authors:  David E Kaplan; Feng Dai; Melissa Skanderson; Ayse Aytaman; Michelle Baytarian; Kathryn D'Addeo; Rena Fox; Kristel Hunt; Astrid Knott; Rajni Mehta; Marcos Pedrosa; Christine Pocha; Adriana Valderrama; Tamar Taddei
Journal:  Dig Dis Sci       Date:  2016-07-12       Impact factor: 3.199

9.  Treatment algorithm based on the multivariate survival analyses in patients with advanced hepatocellular carcinoma treated with trans-arterial chemoembolization.

Authors:  Hasmukh J Prajapati; Hyun S Kim
Journal:  PLoS One       Date:  2017-02-07       Impact factor: 3.240

10.  Analysis of aggressiveness factors in hepatocellular carcinoma patients undergoing transarterial chemoembolization.

Authors:  Yossi Ventura; Brian I Carr; Issac Kori; Vito Guerra; Oren Shibolet
Journal:  World J Gastroenterol       Date:  2018-04-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.